MA53379A - Dispositifs d'administration pour l'administration de médicaments - Google Patents

Dispositifs d'administration pour l'administration de médicaments

Info

Publication number
MA53379A
MA53379A MA053379A MA53379A MA53379A MA 53379 A MA53379 A MA 53379A MA 053379 A MA053379 A MA 053379A MA 53379 A MA53379 A MA 53379A MA 53379 A MA53379 A MA 53379A
Authority
MA
Morocco
Prior art keywords
administration
medicines
devices
administration devices
Prior art date
Application number
MA053379A
Other languages
English (en)
Inventor
Margaux Frances Boyaval
James Chan
Avon Kuo
Lisa Nugent
Brian Stonecipher
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA53379A publication Critical patent/MA53379A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3202—Devices for protection of the needle before use, e.g. caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
    • A61M5/422—Desensitising skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M2005/2006—Having specific accessories
    • A61M2005/2013—Having specific accessories triggering of discharging means by contact of injector with patient body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M2005/206—With automatic needle insertion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M2005/2073—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically preventing premature release, e.g. by making use of a safety lock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
    • A61M2005/3267—Biased sleeves where the needle is uncovered by insertion of the needle into a patient's body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0205—Materials having antiseptic or antimicrobial properties, e.g. silver compounds, rubber with sterilising agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/10—General characteristics of the apparatus with powered movement mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/586—Ergonomic details therefor, e.g. specific ergonomics for left or right-handed users

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA053379A 2018-07-24 2019-07-23 Dispositifs d'administration pour l'administration de médicaments MA53379A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862702637P 2018-07-24 2018-07-24

Publications (1)

Publication Number Publication Date
MA53379A true MA53379A (fr) 2021-06-02

Family

ID=67544399

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053379A MA53379A (fr) 2018-07-24 2019-07-23 Dispositifs d'administration pour l'administration de médicaments

Country Status (8)

Country Link
US (1) US12042645B2 (fr)
EP (1) EP3826701B1 (fr)
CN (1) CN112469454B (fr)
CA (1) CA3103681A1 (fr)
IL (1) IL279128A (fr)
MA (1) MA53379A (fr)
MX (1) MX2021000748A (fr)
WO (1) WO2020023444A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019273833B2 (en) 2018-05-24 2022-03-24 Novartis Ag Automatic drug delivery device

Family Cites Families (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2693186A (en) 1953-05-18 1954-11-02 William M Riker Disposable hypodermic injection syringe
GB770341A (en) * 1954-11-18 1957-03-20 Russell Paul Dunmire Hypodermic syringe
CH328609A (fr) * 1954-12-04 1958-03-15 Dunmire Russell P Seringue hypodermique
US3977401A (en) * 1975-03-25 1976-08-31 William Floyd Pike Injection apparatus
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5496264A (en) * 1993-08-17 1996-03-05 Watson; Robert L. Hemostatic transdermal injection appliance
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
ES2251723T3 (es) 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5989229A (en) 1997-05-28 1999-11-23 Becton, Dickinson And Company Needle cover assembly having self-contained drug applicator
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
PT986644E (pt) 1997-07-23 2007-01-31 Roche Diagnostics Gmbh Preparação de eritropoietina por activação genética endógena com promotores virais
US6030086A (en) 1998-03-02 2000-02-29 Becton, Dickinson And Company Flash tube reflector with arc guide
US6310078B1 (en) 1998-04-20 2001-10-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
ATE339507T1 (de) 1998-06-15 2006-10-15 Gtc Biotherapeutics Inc Erythropoietin-analog-menschliches serum-albumin fusionsprotein
US20050181482A1 (en) 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
PT1783222E (pt) 1998-10-23 2012-07-26 Kirin Amgen Inc Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
PT1813624E (pt) 1998-10-23 2010-10-27 Amgen Inc Métodos e composições para a prevenção e tratamento da anemia
DE69933044T3 (de) 1998-11-27 2016-11-24 Ucb Pharma, S.A. Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
EP1006184A1 (fr) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag Protéines interagissant avec le récepteur de IGF-1, gènes codant pour ces protéines et leurs utilisations
WO2000061637A1 (fr) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Anticorps du recepteur d'erythropoietine
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
AU1099601A (en) 1999-10-22 2001-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
EP1228214A2 (fr) 1999-11-12 2002-08-07 MERCK PATENT GmbH Formes d'erythropoietine dotees de proprietes ameliorees
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
DE60115600T2 (de) 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
AUPQ599700A0 (en) 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
WO2001081405A2 (fr) 2000-04-21 2001-11-01 Amgen Inc. Methodes et compositions destinees a la prevention et au traitement de l'anemie
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
EE200300089A (et) 2000-09-08 2005-02-15 Gryphon Therapeutics, Inc. Sünteetilised erütropoeesi stimuleerivad valgud, nende valmistamismeetodid ning kasutamine
US7271689B1 (en) 2000-11-22 2007-09-18 Fonar Corporation Magnet structure
DE60144439D1 (de) 2000-12-20 2011-05-26 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
BRPI0116728B1 (pt) 2001-01-05 2018-10-30 Pfizer Inc. anticorpos para receptor de fator de crescimento i semelhante à insulina
DE60232870D1 (de) 2001-04-04 2009-08-20 Genodyssee Neue polynukleotide und polypeptide des erythropoietingens
ATE549354T1 (de) 2001-05-11 2012-03-15 Amgen Inc Peptide und damit zusammenhängende an tall-1 bindende moleküle
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
IL160358A0 (en) 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US6796967B2 (en) * 2001-10-22 2004-09-28 Nps Pharmaceuticals, Inc. Injection needle assembly
WO2003055526A2 (fr) 2001-12-21 2003-07-10 Maxygen Aps Conjugues d'erythropoietine
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
DE60312639T2 (de) 2002-01-18 2007-11-29 Pierre Fabre Médicament Antikörper gegen igf-ir und ihre verwendungen
EP1469897A1 (fr) * 2002-01-25 2004-10-27 Michael Jemec Boitier destine a une aiguille retractable et comprenant un moyen permettant de desinfecter la peau au niveau du point de ponction
EP1470232A1 (fr) 2002-01-31 2004-10-27 Oxford Biomedica (UK) Limited Vecteur d'expression de l'erythropoietine physiologiquement regule, destine au traitement de l'anemie
GB0202252D0 (en) 2002-01-31 2002-03-20 Oxford Biomedica Ltd Anemia
ATE363541T1 (de) 2002-03-26 2007-06-15 Lek Tovarna Farmacevtskih Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
CA2480727C (fr) 2002-03-29 2010-06-01 Kumiai Chemical Industry Co., Ltd. Genes codant l'acetolactase synthase
WO2003084477A2 (fr) 2002-03-29 2003-10-16 Centocor, Inc. Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
US20040009902A1 (en) 2002-05-13 2004-01-15 Irving Boime CTP extended erythropoietin
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
JP2005536992A (ja) 2002-06-28 2005-12-08 セントカー・インコーポレーテツド 哺乳動物のｅｐｏ模倣ｃｈ１欠失ミメティボディ、組成物、方法および使用
AU2003280130B2 (en) 2002-06-28 2009-06-11 Centocor, Inc. Mammalian CH1 deleted mimetibodies, compositions, methods and uses
WO2004009627A1 (fr) 2002-07-19 2004-01-29 Cangene Corporation Composes erythropoietiques pegyles
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
CA2824167C (fr) 2002-09-06 2018-09-25 Amgen Inc. Anticorps monoclonal therapeutique anti-il-1r1 humain
WO2005025606A1 (fr) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Erythropoietines a action prolongee pouvant maintenir une activite de protection tissulaire d'une erythropoietine endogene
BR0314106A (pt) 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Polipeptìdeos hasilados, especialmente eritropoietina hasilada
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
US20040071694A1 (en) 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
TWI320716B (en) 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
CN101287484B (zh) 2002-12-20 2012-10-10 安姆根有限公司 抑制肌肉生长抑制素的结合剂
WO2004083248A1 (fr) 2003-03-14 2004-09-30 Pharmacia Corporation Anticorps specifiques du recepteur d'igf-i pour le traitement de cancers
EP1613658B1 (fr) 2003-04-02 2012-03-14 F. Hoffmann-La Roche AG Anticorps contre le recepteur du facteur de croissance 1 analogue a l'insuline et utilisations de ceux-ci
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
WO2005016970A2 (fr) 2003-05-01 2005-02-24 Imclone Systems Incorporated Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP4266028B2 (ja) 2003-05-12 2009-05-20 アフィーマックス・インコーポレイテッド エリスロポエチン受容体に結合する新規ペプチド
JP2007530440A (ja) 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ（エチレングリコール）修飾化合物およびその用途
SI1625156T1 (sl) 2003-05-12 2013-02-28 Affymax, Inc. Peptidi, ki se veĹľejo k eritropoetinskemu receptorju
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
KR20060032140A (ko) 2003-05-30 2006-04-14 센토코 인코포레이티드 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
WO2005001136A1 (fr) 2003-06-04 2005-01-06 Irm Llc Methodes et compositions pour la modulation de l'expression de l'erythropoietine
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
CN102408483B (zh) 2003-07-15 2016-06-08 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
KR101254371B1 (ko) 2003-07-18 2013-05-02 암젠 프레몬트 인코포레이티드 간세포 성장인자에 결합하는 분리된 항체
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US20070275871A1 (en) 2003-08-28 2007-11-29 Biorexis Technology, Inc. Epo Mimetic Peptides and Fusion Proteins
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
EP1687452A4 (fr) 2003-09-30 2008-08-06 Centocor Inc Mimeticorps de noyau-charniere humain, compositions, procedes et applications correspondantes
MXPA06004853A (es) 2003-11-07 2006-07-06 Immunex Corp Anticuerpos que se aglutinan al receptor 4 de interleucina.
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
ES2445948T3 (es) 2003-11-24 2014-03-06 Ratiopharm Gmbh Eritropoyetina glicopegilada
WO2005058967A2 (fr) 2003-12-16 2005-06-30 Pierre Fabre Medicament Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications
EP1548031A1 (fr) 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Erythropoietin identique à la nature
WO2005065239A2 (fr) 2003-12-31 2005-07-21 Centocor, Inc. Nouvelles proteines recombinees avec thiol libre n-terminal
JP2008504008A (ja) 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
US7423139B2 (en) 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
WO2005070451A1 (fr) 2004-01-22 2005-08-04 Zafena Aktiebolag Composition pharmaceutique comprenant une erythropoietine non glycosylee
WO2005084711A1 (fr) 2004-03-02 2005-09-15 Chengdu Institute Of Biological Products Erythropoietine recombinante pegylee a activite in vivo
WO2005092369A2 (fr) 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugues d'hydroxy-ethyl-amidon et d'erythropoietine
US20060002929A1 (en) 2004-03-23 2006-01-05 Khare Sanjay D Monoclonal antibodies
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
JP2008508854A (ja) 2004-04-23 2008-03-27 ケンブリッジ アンティボディー テクノロジー リミテッド エリスロポイエチンタンパク質変異体
DE602005014117D1 (de) 2004-07-07 2009-06-04 Lundbeck As Valby H Neues carbamyliertes epo und verfahren zu dessen herstellung
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
US20060073563A1 (en) 2004-09-02 2006-04-06 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
EP1812461A2 (fr) 2004-11-10 2007-08-01 AplaGen GmbH Molécules favorisant l'hématopoiese
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CA2612449A1 (fr) 2005-06-17 2006-12-28 Imclone Systems Incorporated Antagonistes de recepteur pour le traitement de cancer osseux metastatique
WO2007000328A1 (fr) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Anticorps se fixant à un épitope sur un récepteur de facteur de croissance insulinomimétique de type 1 et leurs utilisations
AU2006270009A1 (en) 2005-07-18 2007-01-25 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US8162899B2 (en) 2006-05-18 2012-04-24 Hyprotek, Inc. Intravascular line and port cleaning methods, methods of administering an agent intravascularly, methods of obtaining/testing blood, and devices for performing such methods
MX2008014744A (es) 2006-05-19 2009-02-10 Glycofi Inc Composiciones de eritrocpoyetina.
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
WO2008057458A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
CA2667894A1 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
US20100040611A1 (en) 2006-11-07 2010-02-18 Sparrow Carl P Antagonists of pcsk9
WO2008133647A2 (fr) 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonistes de pcsk9
CA2671538A1 (fr) 2006-12-14 2008-06-26 Leonard G. Presta Anticorps anti-tslp technique
CN101679527A (zh) 2007-04-13 2010-03-24 诺瓦提斯公司 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法
JP2010530233A (ja) 2007-06-20 2010-09-09 アイアールエム・リミテッド・ライアビリティ・カンパニー アレルギー疾患を処置する方法および組成物
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2205639B1 (fr) 2007-10-26 2015-12-23 Merck Sharp & Dohme Corp. Anti-pcsk9 et méthodes de traitement de troubles du métabolisme lipidique et du cholestérol
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US20120219558A1 (en) 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
WO2011053783A2 (fr) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Antagonistes et variants ax213 et ax132 pcsk9
CN102596249A (zh) 2009-10-30 2012-07-18 默沙东公司 Ax1和ax189 pcsk9拮抗剂和变体
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
SG183867A1 (en) 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2012054438A1 (fr) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
KR20130118925A (ko) 2010-12-22 2013-10-30 제넨테크, 인크. 항-pcsk9 항체 및 사용 방법
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
AU2012214251A1 (en) 2011-02-11 2013-09-12 Novartis Ag PCSK9 antagonists
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
ES2875957T3 (es) 2012-12-20 2021-11-11 Amgen Inc Agonistas del receptor APJ y usos de los mismos
MX380644B (es) 2013-03-14 2025-03-12 Amgen Inc Composiciones y metodos de variantes de inhibidor tisular de la metaloproteinasa tipo tres (timp-3).
US20140274874A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
WO2015048799A1 (fr) 2013-09-30 2015-04-02 Medimop Medical Projects Ltd. Mécanisme de repli d'aiguille pour injecteur automatique

Also Published As

Publication number Publication date
CN112469454B (zh) 2024-01-26
US12042645B2 (en) 2024-07-23
WO2020023444A1 (fr) 2020-01-30
CA3103681A1 (fr) 2020-01-30
IL279128A (en) 2021-01-31
EP3826701A1 (fr) 2021-06-02
CN112469454A (zh) 2021-03-09
MX2021000748A (es) 2021-03-26
US20210369982A1 (en) 2021-12-02
EP3826701B1 (fr) 2026-04-08

Similar Documents

Publication Publication Date Title
MA53375A (fr) Dispositifs d'administration pour l'administration de médicaments
MA50557A (fr) Pistons pour dispositifs d'administration de médicament
EP3826589A4 (fr) Dispositif ophtalmique pour l'administration de médicaments
EP3522825A4 (fr) Dispositifs implantables pour l'administration de médicaments caractérisés par une moindre libération massive et soudaine
EP3781021A4 (fr) Dispositifs de croisement d'occlusion
EP3621656A4 (fr) Formulation pour l'administration d'un médicament pour les yeux
EP3377009A4 (fr) Structures poreuses pour dispositifs d'administration de médicament à libération prolongée
EP3740272A4 (fr) Orifice d'injection pour administration thérapeutique
EP3710079A4 (fr) Systèmes, dispositifs, formulations et procédés pour l'administation contrôlée de médicaments
EP4094795C0 (fr) Dispositifs d'intubation
EP3334499A4 (fr) Conjugués bioactifs pour l'administration d'oligonucléotides
EP3431075C0 (fr) Forme galénique d'édaravone
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
EP3400051A4 (fr) Mécanismes d'assistance au remplissage et interfaces verrouillées pour dispositifs d'administration de médicament
EP3852655A4 (fr) Dispositifs d'exosquelette extensibles pour administration de médicaments
EP3731846A4 (fr) Systèmes d'administration de médicament pour le traitement d'infections
MA45472A (fr) Systèmes d'administration pour la libération contrôlée de médicaments
EP3600263A4 (fr) Systèmes de microcellules pour l'administration de molécules actives
EP3759568A4 (fr) Suspensions pour dispositifs d'affichage
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
EP3509573A4 (fr) Compositions pharmaceutiques pour l'administration d'un peptide
EP3898991A4 (fr) Administration périnéale de résinifératoxine pour le traitement de la douleur maladaptative
HUE059584T2 (hu) Gyógyszerészeti készítmény vérszegénység kezelésére
EP3500291A4 (fr) Formulations pour l'administration par voie orale d'agents actifs
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques